April 14th 2025
In the United States, maralixibat (Livmarli; Mirum Pharmaceuticals) is approved to treat both ALGS and PFIC, now in liquid and tablet formulations.
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Reading between the lines: teaching teens to use nutrition facts labels
March 4th 2025Colleen Sloan, PA-C, RDN, emphasizes the importance of learning to spot added sugars, compare portion sizes, and recognize misleading marketing claims to give patients a practical tool to take ownership of their health.
Overcoming pediatric obesity: Behavioral strategies and GLP-1 support
October 4th 2024Kay Rhee, MD, discusses the challenges of pediatric obesity treatment, highlighting the role of biological and environmental factors, behavioral interventions, and the potential benefits of GLP-1 medications in weight management for children and teens.